CoChat

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer

Open access
Eatock, M.M., Tebbutt, N.C., Bampton, C.L., Strickland, A.H., Valladares-Ayerbes, M., Swieboda-Sadlej, A., Van Cutsem, E., Nanayakkara, N., Sun, Y.-N., Zhong, Z.D., Bass, M.B., Adewoye, A.H., Bodoky, G. · 2013 · Annals of Oncology

The DOI matches its Crossref record; 41 of the 44 references it cites were found in a registry or an index.

Abstract

Background We evaluated AMG 386, an investigational peptibody that neutralizes the interaction between angiopoietins-1 and -2 and the Tie2 receptor, combined with cisplatin/capecitabine (CX) as first-line treatment for metastatic gastro-oesophageal cancer.Patients and methods Patients with metastatic gastric, gastro-oesophageal junction, or distal oesophageal adenocarcinoma were randomized 1:1:1 to CX (cisplatin 80 mg/m(2) IV Q3W; capecitabine 1000 mg/m(2) P.O. BID for 14 days Q3W) plus intravenous AMG 386 10 mg/kg QW (Arm A) or 3 mg/kg QW (Arm B), or placebo QW (Arm C). The primary end point was estimated progression-free survival (PFS).Results A total of 171 patients were enrolled. Median estimated PFS in Arms A, B, and C was 4.2, 4.9, and 5.2 months, respectively (hazard ratio for Arms A+B combined versus Arm C, 0.98; 95% CI 0.67-1.43; P = 0.92). Objective response rates were 27% (Arm A), 43% (Arm B), and 35% (Arm C). Incidence of grade ≥3 adverse events was 80% in Arm A, 84% in Arm B, and 75% in Arm C. There was no evidence of pharmacokinetic interactions.Conclusions In this study, PFS and ORR were estimated to be similar with AMG 386 plus CX and placebo plus CX treatment. Compared with placebo, toxicity of AMG 386 plus CX was greater but manageable.Previous presentation The results of this study have not been previously published or submitted for publication elsewhere. The results were presented in part at the Gastrointestinal Cancers Symposium, San Francisco, CA, January 20-22, 2011.Clinical trial registration ClinicalTrials.gov registration number: NCT00583674.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mds502

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 1

  1. Okugawa Y, Miki C, Toiyama Y et al.. Serum soluble VCAM-1 as a valuable prognostic marker in colorectal carcinoma [abstract]. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA, 2008.

Cited by

See all 66

Metadata

Authors
Eatock, M. M., Tebbutt, N. C., Bampton, C. L., Strickland, A. H., Valladares-Ayerbes, M., Swieboda-Sadlej, A., Van Cutsem, E., Nanayakkara, N., Sun, Y.-N., Zhong, Z. D., Bass, M. B., Adewoye, A. H., & Bodoky, G.
Affiliations
  • Belfast City Hospital (GB)
  • Northern Health (AU)
  • Monash Medical Centre (AU)
  • IQVIA (United States) (US)
  • Amgen (United States) (US)
  • Unified Szent István and Szent László Hospital (HU)
Corresponding author
Eatock, M.M.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2013-03
Volume
24
Issue
3
Pages
710-718
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2061877116
Cited by
64
References
44
Citations by year
2025: 3 · 2024: 1 · 2023: 5 · 2022: 4 · 2021: 7 · 2019: 5 · 2018: 4 · 2017: 7 · 2016: 3 · 2015: 8 · 2014: 8 · 2013: 8
FWCI
6.19
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
Funders
Amgen Inc
Topics
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
trebananib, angiopoietin-2, angiopoietin-1, Tie2 receptor, peptibody, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, cisplatin, capecitabine, first-line therapy, progression-free survival, objective response rate, adverse events
MeSH terms
Capecitabine, Adenocarcinoma, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cardiovascular Diseases, Cisplatin, Deoxycytidine, Double-Blind Method, Esophageal Neoplasms, Female, Fluorouracil, Humans, Male, Middle Aged, Recombinant Fusion Proteins, Stomach Neoplasms, Treatment Outcome, Disease-Free Survival, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. https://app.cochat.ai/papers/10.1093/annonc/mds502
The paper
Eatock, M. M., Tebbutt, N. C., Bampton, C. L., Strickland, A. H., Valladares-Ayerbes, M., Swieboda-Sadlej, A., Van Cutsem, E., Nanayakkara, N., Sun, Y.-N., Zhong, Z. D., Bass, M. B., Adewoye, A. H., & Bodoky, G. (2013). Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mds502

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.